| | Item No | Recommendation |
|------------------------|------------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract |
| | | :Yes |
| | | (b) Provide in the abstract an informative and balanced summary of what was done |
| | | and what was found: Yes |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported :Yes |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses: Yes |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper :Yes |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, |
| | | exposure, follow-up, and data collection :Yes |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of |
| • | | selection of participants. Describe methods of follow-up: Yes |
| | | Case-control study—Give the eligibility criteria, and the sources and methods of |
| | | case ascertainment and control selection. Give the rationale for the choice of cases |
| | | and controls: Yes |
| | | Cross-sectional study—Give the eligibility criteria, and the sources and methods of |
| | | selection of participants: No |
| | | (b) Cohort study—For matched studies, give matching criteria and number of |
| | | exposed and unexposed : No |
| | | Case-control study—For matched studies, give matching criteria and the number of |
| | | controls per case : NA |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect |
| | | modifiers. Give diagnostic criteria, if applicable: Yes |
| Data sources/ | 8* | For each variable of interest, give sources of data and details of methods of |
| measurement | | assessment (measurement). Describe comparability of assessment methods if there |
| | | is more than one group : Yes |
| Bias | 9 | Describe any efforts to address potential sources of bias : Yes |
| Study size | 10 | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, |
| | | describe which groupings were chosen and why: Yes |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding |
| | | : Yes |
| | | (b) Describe any methods used to examine subgroups and interactions: Yes |
| | | (c) Explain how missing data were addressed |
| | | (d) Cohort study—If applicable, explain how loss to follow-up was addressed: No |
| | | Case-control study—If applicable, explain how matching of cases and controls was |
| | | addressed: NA |
| | | Cross-sectional study—If applicable, describe analytical methods taking account of |
| | | sampling strategy: NA |
| | | (e) Describe any sensitivity analyses : NA |
| | | (2) Describe any sometimely unaryson . 1711 |

| Results | | |
|------------------|-----|---|
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed: Yes |
| | | (b) Give reasons for non-participation at each stage NA |
| | | (c) Consider use of a flow diagram NA |
| Descriptive | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information |
| data | | on exposures and potential confounders: Yes |
| | | (b) Indicate number of participants with missing data for each variable of interest: Yes |
| | | (c) Cohort study—Summarise follow-up time (eg, average and total amount): NA |
| Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time |
| | | Case-control study—Report numbers in each exposure category, or summary measures of exposure: NA |
| | | Cross-sectional study—Report numbers of outcome events or summary measures: NA |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included :Yes |
| | | (b) Report category boundaries when continuous variables were categorized : Yes |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period :Yes |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses :Yes |
| Discussion | | |
| Key results | 18 | Summarise key results with reference to study objectives : Yes |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias: Yes |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence: Yes |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results: No |
| Other informati | ion | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based : Yes |

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| Identifying Inform | ation | | | | | |
|---|-------------------|--|----------------------------|--------------|--|--|
| Given Name (First Name) Zoheb | 2. Surnar Kazi | ne (Last Nar | ne) | | 3. Date 02-May-2016 | |
| 4. Are you the corresponding author? | Yes | Yes No Corresponding Author's Nam Priya S. Kishnani | | | or's Name | |
| 5. Manuscript Title Durable and sustained immune tolerand | ce to ERT i | n Pompe d | isease with entre | nched im | mune responses | |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | ow it) | | | | | |
| Section 2. The Work Under Co | | | LP de . | | | |
| The Work Under Co | onsidera | tion for P | ublication | | | |
| Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intereing If yes, please fill out the appropriate info Excess rows can be removed by pressing | but not linst? | nited to gran Yes pelow. If yo | its, data monitoring No | g board, sti | udy design, manuscript preparation, | |
| Name of Institution/Company | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
| Genzyme | ✓ | | | | This research was supported by a grant from the Genzyme Corpration, a Sanofi Company (Cambridge, MA), and in part by the Lysosomal Disease Netowrk (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | |



| Name of Institution/Company | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
|---|-----------|------------------------|-------------------------------------|--------------------------|--|--|
| NIH | ✓ | | | | This research was supported by a grant from the Genzyme Corpration, a Sanofi Company (Cambridge, MA), and in part by the Lysosomal Disease Netowrk (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | |
| Place a check in the appropriate boxes in of compensation) with entities as describe | the table | to indicate | e whether you hans. Use one line fo | ive financ or each er | ntity; add as many lines as you need | |
| clicking the "Add +" box. You should report of the any relevant conflicts of interest | | onships tha Yes 🕡 I | - | uring the | 2 36 months prior to publication. | |
| · | | | | | | |
| Section 4. Intellectual Propert | y Pate | ents & Cop | oyrights | | | |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo | | | | | | |



| Section 5. Polationships not solvered above |
|--|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section |
| Section 6. Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Kazi reports grants from Genzyme, grants from NIH, during the conduct of the study; . |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inform | ation | | | | |
|---|---------------------|-------------------|----------------------------|----------|--|
| 1. Given Name (First Name) Sean | 2. Surnar Prater | ne (Last Nar | ne) | | 3. Date 20-April-2016 |
| 4. Are you the corresponding author? | Yes | √ No | Correspond Priya S. Kis | • | |
| 5. Manuscript Title Durable and sustained immune tolerand | ce to ERT i | n Pompe d | lisease with entre | nched im | mune responses |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | ow it) | | | | |
| Section 2. The Work Under Co | onsidera | tion for P | ublication | | |
| Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere | but not lin | nited to grar | | | |
| If yes, please fill out the appropriate info Excess rows can be removed by pressing | | | u have more thar | one enti | ty press the "ADD" button to add a row. |
| Name of Institution/Company | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments |
| Genzyme | ✓ | | | | This research was supported by a grant from the Genzyme Corpration, a Sanofi Company (Cambridge, MA), and in part by the Lysosomal Disease Netowrk (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the |



Name of Institution/Company

ICMJE Form for Disclosure of Potential Conflicts of Interest

Grant?

| NIH | ✓ | | | gra a S and Ne the Rai Ne thr (OF Ad (NC Ne (NI Dia Dis sol aut rep Na fur dat | s research was supported by a sint from the Genzyme Corpration, anofi Company (Cambridge, MA), d in part by the Lysosomal Disease towrk (U54NS065768) is a part of National Institutes of Health (NIH) is Disease Clinical Research twork (RDCRN), supported ough collaboration between the HOffice of Rare Diseases Research RDR) at the National Center for vancing Translational Science CATS), the National Institute of the User and Digestive and Stroke NDS) and National Institute of Sibetes and Digestive and Kidney eases (NIDDK). The content is sely the responsibility of the chors and does not necessarily present the official views of the tional Institute of Health. The siders had no role in study design, as collection and analysis, decision oublish, or preparation of the nuscript. |
|--|---------------------------|------------------------|---|--|--|
| | | | | | |
| Section 3. Relevant financial a | ctivities | s outside | the submitted | work. | |
| Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interests. | oed in the ort relatio | instruction | ns. Use one line fo It were present d | or each entity | r; add as many lines as you need by |
| Section 4. Intellectual Propert | ty Pate | ents & Co _l | pyrights | | |
| Do you have any patents, whether plann | ied, pend | ing or issue | ed, broadly releva | nt to the wo | rk? ✓ Yes |
| If yes, please fill out the appropriate info Excess rows can be removed by pressing | | | u have more than | one entity p | oress the "ADD" button to add a row. |
| Patent? Pendin | | | sed?Royalties? | Licensee? | Comments |
| 2013003/329 | ✓ | | | | |

Personal Non-Financial

Support?

Fees?

Other?

Comments



| Section 5. Relationships not covered above |
|---|
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| |
| |
| |
| |
| |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Non-Financial Support: Examples include drugs/equipment

Kobori 1



| Section 1. Identifying Inform | nation | |
|---|---|---|
| Given Name (First Name) Joyce | 2. Surname (Last Name) Kobori | 3. Date 02-May-2016 |
| 4. Are you the corresponding author? | Yes ✓ No | Corresponding Author's Name Priya S. Kishnani |
| 5. Manuscript Title Durable and sustained immune toleran | ce to ERT in Pompe diseas | e with entrenched immune responses |
| 6. Manuscript Identifying Number (if you kr 86821-INS-CMED-1 | now it) | |
| | | |
| Section 2. The Work Under Co | onsideration for Public | ation |
| | but not limited to grants, da | a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation, |
| Section 3. Relevant financial | activities outside the s | ubmitted work. |
| of compensation) with entities as descri | ibed in the instructions. Us port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication . |
| Section 4. Intellectual Proper | rty Patents & Copyri <u>c</u> | ıhts |
| Do you have any patents, whether plan | | |

Kobori 2



| Section 5. Relationships not covered above |
|---|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Kobori has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Kobori 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Viskochil, MD



| Section 1. Identifying Inform | nation | |
|--|--|--|
| 1. Given Name (First Name) David H | 2. Surname (Last Name) Viskochil, MD | 3. Date 26-April-2016 |
| 4. Are you the corresponding author? | ☐ Yes 🗸 No | Corresponding Author's Name Priya S. Kishnani |
| 5. Manuscript Title Durable and sustained immune tolerar | nce to ERT in Pompe diseas | e with entrenched immune responses |
| 6. Manuscript Identifying Number (if you k 86821-INS-CMED-1 | now it) | _ |
| Section 2. The Work Under C | | |
| The Work Under C | onsideration for Public | cation |
| | g but not limited to grants, da | a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation, |
| | | |
| Section 3. Relevant financial | activities outside the s | ubmitted work. |
| of compensation) with entities as descr | ribed in the instructions. Us port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |
| Section 4. Intellectual Prope | rty Patents & Copyric | ihts |
| menectual riope | rty Tatents & copyrig | Jines |
| Do you have any patents, whether plan | nned, pending or issued, br | oadly relevant to the work? Yes V No |

Viskochil, MD 2



| Coation F | |
|------------------|--|
| Section 5. | Relationships not covered above |
| | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work? |
| Yes, the follow | wing relationships/conditions/circumstances are present (explain below): |
| ✓ No other rela | tionships/conditions/circumstances that present a potential conflict of interest |
| | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships. |
| Section 6. | Disclosure Statement |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box |
| David H. Viskoch | il, MD has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Viskochil, MD



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Bailey 1



| Section 1. Identifying Inform | nation | | | |
|---|----------------------------------|--|--|--|
| 1. Given Name (First Name) Carrie | 2. Surname (Last Name) Bailey | 3. Date 22-April-2016 | | |
| 4. Are you the corresponding author? | Yes ✓ No | Corresponding Author's Name Priya S. Kishnani | | |
| 5. Manuscript Title Durable and sustained immune toleran | ce to ERT in Pompe diseas | e with entrenched immune responses | | |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | now it) | | | |
| | | | | |
| Section 2. The Work Under Co | onsideration for Public | ation | | |
| Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No | | | | |
| Section 3. Relevant financial | activities outside the s | ubmitted work. | | |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo | | | | |
| Section 4. Intellectual Proper | rty Patents & Copyrig | yhts | | |
| Do you have any patents, whether plant | ned, pending or issued, br | oadly relevant to the work? Yes V No | | |

Bailey 2



| Section 5. Polationships not solvered above |
|--|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Carrie Bailey has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Bailey 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Gera 1



| Section 1. Identifying Inform | nation | |
|---|---|--|
| 1. Given Name (First Name) Renuka | 2. Surname (Last Name) Gera | 3. Date 22-April-2016 |
| 4. Are you the corresponding author? | Yes ✓ No | Corresponding Author's Name Priya S. Kishnani |
| 5. Manuscript Title Durable Sustained Immune Tolerance t | o ERT in Pompe disease wi | ith Entrenched Immune responses |
| 6. Manuscript Identifying Number (if you kr 86821-INS-CMED-1 | now it) | |
| | | |
| Section 2. The Work Under Co | onsideration for Public | ation |
| | but not limited to grants, da | a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation, |
| Section 3. Relevant financial | activities outside the s | ubmitted work. |
| of compensation) with entities as descri | ibed in the instructions. Us port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication . |
| Section 4. Intellectual Proper | rty Patents & Copyri <u>c</u> | ahts |
| Do you have any patents, whether plan | | |

Gera 2



| Section 5. | |
|------------------|---|
| Section 5. | Relationships not covered above |
| | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |
| Yes, the follo | wing relationships/conditions/circumstances are present (explain below): |
| ✓ No other rela | tionships/conditions/circumstances that present a potential conflict of interest |
| | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships. |
| | |
| Section 6. | Disclosure Statement |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box |
| Dr. Gera has not | hing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Gera 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Stockton 1



| Section 1. Identifying Inform | ation | | |
|---|--|-------------------------|---|
| Given Name (First Name) David | 2. Surname (Last Name) Stockton | | 3. Date 19-April-2016 |
| 4. Are you the corresponding author? | ☐ Yes ✓ No | Corresponding Autho | or's Name |
| 5. Manuscript Title Durable and sustained immune toleran | ce to ERT in Pompe disea: | se with entrenched im | mune responses |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | ow it) | _ | |
| | | | |
| Section 2. The Work Under Co | onsideration for Publi | cation | |
| Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere | but not limited to grants, d | | |
| Section 3. Relevant financial | activities outside the | submitted work. | |
| Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should repart there any relevant conflicts of interesting please fill out the appropriate info | bed in the instructions. Uport relationships that we est? Yes No | se one line for each en | ntity; add as many lines as you need by |
| , | | | |
| Name of Entity | Grant | n-Financial other? | Comments |
| Genzyme | ✓ | | |
| Genzyme | ✓ | | |
| | | | |
| Section 4. Intellectual Proper | ty Patents & Copyri | ghts | |
| Do you have any patents, whether plant | ned, pending or issued, b | roadly relevant to the | work? Yes 🗸 No |

Stockton 2



| Costion F | |
|------------------|---|
| Section 5. | Relationships not covered above |
| | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work? |
| Yes, the follow | wing relationships/conditions/circumstances are present (explain below): |
| ✓ No other rela | tionships/conditions/circumstances that present a potential conflict of interest |
| | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships. |
| Section 6. | Disclosure Statement |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box |
| Dr. Stockton rep | orts grants from Genzyme, personal fees from Genzyme, outside the submitted work; . |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Stockton 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

McIntosh 1



| Section 1. Identifying Inform | nation | |
|---|------------------------------------|--|
| 1. Given Name (First Name) Paul | 2. Surname (Last Name) McIntosh | 3. Date 21-April-2016 |
| 4. Are you the corresponding author? | Yes ✓ No | Corresponding Author's Name Priya S. Kishnani |
| 5. Manuscript Title Durable and sustained immune toleran | ce to ERT in Pompe diseas | e with entrenched immune responses |
| 6. Manuscript Identifying Number (if you kr 86821-INS-CMED-1 | now it) | |
| | | |
| Section 2. The Work Under Co | onsideration for Publi | cation |
| any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere | but not limited to grants, da | a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation, |
| Section 3. Relevant financial | activities outside the | submitted work. |
| of compensation) with entities as descri | ibed in the instructions. Us | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Are there any relevant conflicts of interest | | |
| If yes, please fill out the appropriate info | ormation below. | |
| Name of Entity | Grant• | n-Financial other? Comments |
| Genzyme | | Travel Assistance for Genzyme's Patient Speakers Bureau |
| | | |
| Section 4. Intellectual Proper | rty Patents & Copyri | ghts |
| Do you have any patents, whether plan | ned, pending or issued, br | oadly relevant to the work? Yes V No |

McIntosh 2



| Section 5. | |
|------------------|--|
| Section 5. | Relationships not covered above |
| | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |
| Yes, the follow | wing relationships/conditions/circumstances are present (explain below): |
| ✓ No other rela | tionships/conditions/circumstances that present a potential conflict of interest |
| | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships. |
| Section 6. | Disclosure Statement |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box |
| PM receives trav | el assistance for speaking engagements as a member of Genzyme's Patient Speakers Bureau. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

McIntosh 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Rosenberg 1



| Section 1. Identifying Inform | nation | | | |
|---|---|--|--|--|
| 1. Given Name (First Name) Amy | 2. Surname (Last Name) Rosenberg | 3. Date 18-April-2016 | | |
| 4. Are you the corresponding author? | Yes ✓ No | Corresponding Author's Name Priya S. Kishnani | | |
| 5. Manuscript Title Durable and sustained immune toleran | ce to ERT in Pompe diseas | e with entrenched immune responses | | |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | now it) | | | |
| | | | | |
| Section 2. The Work Under Co | onsideration for Public | ation | | |
| Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No | | | | |
| Section 3. Relevant financial | activities outside the s | ubmitted work. | | |
| of compensation) with entities as descri | ibed in the instructions. Us port relationships that wer | ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication . | | |
| Section 4. Intellectual Proper | rty Patents & Copyrig | yhts | | |
| Do you have any patents, whether plant | | | | |

Rosenberg 2



| Section 5. Relationships not covered above |
|--|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Rosenberg has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rosenberg 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inform | ation | | | | |
|---|----------------------------------|------------------------|------------------------------------|---|----------|
| 1. Given Name (First Name) Priya | 2. Surname (Last Nar Kishnani | me) | | 3. Date 22-April-2016 | |
| 4. Are you the corresponding author? | ✓ Yes No | | | | |
| 5. Manuscript Title Durable and sustained immune tolerand | ce to ERT in Pompe c | lisease with entre | nched immur | ne responses | |
| 6. Manuscript Identifying Number (if you kn 86821-INS-CMED-1 | ow it) | | | | |
| | | | | | |
| Section 2. The Work Under Co | onsideration for P | ublication | | | |
| Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere | but not limited to gran | | | | tc.) for |
| If yes, please fill out the appropriate info | | | one entity n | ress the "ADD" button to add | a row |
| Excess rows can be removed by pressing | | a nave more than | one entity pi | ress the ADD button to add | a iow. |
| Name of Institution/Company | Grant? Personal Fees? | Non-Financial Support? | Other? Co | omments | |
| Genzyme Corporation (Sanofi Aventis) | | | rese hon Corp mer Dise | a S. Kishnani has received earch/grant support and foraria from Genzyme poration. Priya S. Kishnani is a mber of the Pompe and Gaucher ease Registry Advisory Board for azyme Corporation | |



| Name of Institution/Company | Grant • | Fees? | Support? | Other • | Comments |
|--|------------|-------------|---------------------|------------|--|
| NIH | ✓ | | | | This research was supported by a grant from the Genzyme Corpration, a Sanofi Company (Cambridge, MA), and in part by the Lysosomal Disease Netowrk (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Section 3. Relevant financial a | activities | s outside ' | the submitted | work. | |
| Place a check in the appropriate boxes ir of compensation) with entities as describ clicking the "Add +" box. You should rep | bed in the | instruction | ns. Use one line fo | or each er | ntity; add as many lines as you need by |
| Are there any relevant conflicts of intere | | | No | | |
| If yes, please fill out the appropriate info | rmation b | elow. | | | |
| | | | | | |

| Name of Entity | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
|-------------------------------|--------------|-------------------|------------------------|----------|----------------|--|
| PTC Therapeutics | | ✓ | | | | |
| Baebies, Inc. | | | | ✓ | Advisory Board | |
| Roche | | ✓ | | | | |
| Alexion Pharmaceuticals, Inc/ | | \checkmark | | | | |
| Amicus Therapeutics | | ✓ | | | | |
| Shire Pharmaceuticals | \checkmark | ✓ | | | | |



| Name of Entity | G | ranic | • | on-Financial Support? | Other? | Comments | | | |
|---|------------|----------|-----------|-----------------------|---------|--|--|--|--|
| Synageva | | | ✓ | | | FDA Advisory Board | | | |
| Section 4. | | | | | | | | | |
| Intellectual | Property - | Patent | s & Copyr | ights | | | | | |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button. | | | | | | | | | |
| Patent? | Pending? | Issued? | Licensed | Royalties? | License | e? Comments | | | |
| 20150037329 (US Patent #8,809,282) | | √ | | | | US Patent #8,809,282, issued August 19, 2014, "Method of Reducing Titers of Antibodies Specific for a Therapeutic Agent," Inventors: Priya S. Kishnani, Surhad C. Banugaria, Dwight D, Koeberl, Sean N. Prater. | | | |
| Section 5. Relationships not covered above | | | | | | | | | |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? | | | | | | | | | |
| Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest | | | | | | | | | |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. | | | | | | | | | |



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Kishnani reports grants and personal fees from Genzyme Corporation (Sanofi Aventis), grants from NIH, during the conduct of the study; personal fees from PTC Therapeutics, other from Baebies, Inc., personal fees from Roche, personal fees from Alexion Pharmaceuticals, Inc/, personal fees from Amicus Therapeutics, grants and personal fees from Shire Pharmaceuticals, personal fees from Synageva, outside the submitted work; In addition, Dr. Kishnani has a patent 20150037329 (US Patent #8,809,282) issued.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.